Vistagen Therapeutics (VTGN) Return on Equity (2017 - 2025)
Historic Return on Equity for Vistagen Therapeutics (VTGN) over the last 12 years, with Q4 2025 value amounting to 1.14%.
- Vistagen Therapeutics' Return on Equity fell 6000.0% to 1.14% in Q4 2025 from the same period last year, while for Dec 2025 it was 1.14%, marking a year-over-year decrease of 6000.0%. This contributed to the annual value of 0.56% for FY2025, which is 900.0% down from last year.
- Latest data reveals that Vistagen Therapeutics reported Return on Equity of 1.14% as of Q4 2025, which was down 6000.0% from 1.01% recorded in Q3 2025.
- Over the past 5 years, Vistagen Therapeutics' Return on Equity peaked at 0.19% during Q1 2021, and registered a low of 4.9% during Q2 2023.
- In the last 5 years, Vistagen Therapeutics' Return on Equity had a median value of 0.67% in 2022 and averaged 1.15%.
- In the last 5 years, Vistagen Therapeutics' Return on Equity plummeted by -229200bps in 2021 and then soared by 46000bps in 2024.
- Quarter analysis of 5 years shows Vistagen Therapeutics' Return on Equity stood at 0.46% in 2021, then tumbled by -446bps to 2.53% in 2022, then skyrocketed by 84bps to 0.4% in 2023, then crashed by -35bps to 0.54% in 2024, then plummeted by -110bps to 1.14% in 2025.
- Its Return on Equity was 1.14% in Q4 2025, compared to 1.01% in Q3 2025 and 0.88% in Q2 2025.